---
title: "002437.SZ (002437.SZ) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/002437.SZ/news.md"
symbol: "002437.SZ"
name: "002437.SZ"
parent: "https://longbridge.com/zh-CN/quote/002437.SZ.md"
datetime: "2026-03-13T01:34:05.244Z"
locales:
  - [en](https://longbridge.com/en/quote/002437.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002437.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002437.SZ/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/002437.SZ/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/002437.SZ/news.md)


# 002437.SZ (002437.SZ) — 相关新闻

### [Zhitong A-share restricted stock release overview | March 12](https://longbridge.com/zh-CN/news/278797873.md)
*2026-03-12T01:02:15.000Z*
> On March 12, a total of 1 listed company had its restricted shares unlocked, with a total market value of approximately 

### [GLORIA PHARMA. expects net profit to grow by more than 50% year-on-year in 2025, with significant or steady growth in sales of some core products](https://longbridge.com/zh-CN/news/273082485.md)
*2026-01-20T12:15:22.000Z*
> GLORIA PHARMA. expects a net profit of 350 million to 420 million yuan in 2025, a year-on-year increase of over 50%. The

### [GLORIA PHARMA. issued a preliminary profit increase announcement, expecting a net profit attributable to the parent company of 350 million to 420 million yuan for the fiscal year 2025, an increase of 50.37% to 80.44%](https://longbridge.com/zh-CN/news/273060763.md)
*2026-01-20T09:31:03.000Z*
> GLORIA PHARMA. expects the net profit attributable to the parent company for the fiscal year 2025 to be between 350 mill

### [GLORIA PHARMA: Whether the largest shareholder will continue to increase their holdings will depend on the company's development and market conditions](https://longbridge.com/zh-CN/news/270685109.md)
*2025-12-24T03:48:14.000Z*
> GLORIA PHARMA (002437) recently disclosed in its investor relations activity record that the company received research v

### [Overview of Important Announcements from Listed Companies on November 21](https://longbridge.com/zh-CN/news/266940829.md)
*2025-11-21T13:46:15.000Z*
> On November 21, multiple listed companies released important announcements. Chaozhuo Aerospace Technology will be suspen

### [GLORIA PHARMA General Manager Guo Leifeng and his concerted actors successfully bid for 25 million shares of the company](https://longbridge.com/zh-CN/news/266884392.md)
*2025-11-21T09:32:03.000Z*
> GLORIA PHARMA announced that the company's general manager Guo Leifeng and his concerted actor Tibet Yupai Enterprise Ma

### [GLORIA PHARMA: Guolei Feng and Tibet Yupan collectively increased their holdings by 1.12%](https://longbridge.com/zh-CN/news/266881731.md)
*2025-11-21T09:15:43.000Z*
> GLORIA PHARMA announced that the company's director, general manager, and financial officer Guo Leifeng, along with the 

### [Secondary transfer to settle debts, has GLORIA PHARMA found a solution for the over 100 million owed?](https://longbridge.com/zh-CN/news/264792603.md)
*2025-11-07T06:14:53.000Z*
> GLORIA PHARMA announced that it will resolve the debt dispute with Qingdao Pusheng Puli through an agreement, involving 

### [Behind GLORIA PHARMA's third-quarter report showing profit growth: Financial investments earned a staggering 377 million yuan "blood transfusion," while the revenue decline dilemma remains difficult to resolve](https://longbridge.com/zh-CN/news/264604224.md)
*2025-11-06T09:24:15.000Z*
> GLORIA PHARMA's third quarter report for 2025 shows that although operating revenue fell by 10.36% year-on-year to 1.665